Scholars@Duke
Pamela Susan Douglas

Pamela Susan Douglas CV

Ursula Geller Distinguished Professor of Research in Cardiovascular Diseases
Medicine, Cardiology
Duke Box 17969, Durham, NC 27705
300 W. Morgan St Room 841, Durham, NC 27701
CV

Scholarly Works - Conferences

Machine Learning Computer Vision Point of Care Decision Support of Echocardiographic Identification of Hypertrophic Cardiomyopathy.

Conference JACC Adv · May 2025 BACKGROUND: Hypertrophic cardiomyopathy (HCM) remains underdiagnosed, and artificial intelligence tools for echocardiographic recognition have been hampered by lack of insight into drivers of model predictions and ease of implementation. OBJECTIVES: The pu ... Full text Link to item Cite

Patient-Prosthesis Mismatch After Surgical Aortic Valve Replacement: Analysis of the PARTNER Trials.

Conference Ann Thorac Surg · June 2024 BACKGROUND: Our objective was to compare the impact of patient-prosthesis mismatch (PPM) for 2 years after surgical aortic valve replacement within the prospective, randomized Placement of Aortic Transcatheter Valves (PARTNER) trials. METHODS: Surgical aor ... Full text Link to item Cite

Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).

Conference Journal of Clinical Oncology · May 20, 2019 541 Background: Breast cancer therapy causes marked impairments in CV function predisposing to elevated risk of CV morbidity. We investigated the effects of two AT dosing regimens on CV function in post-treatment patients with op ... Full text Cite

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.

Conference Am J Med · December 2017 BACKGROUND: Cancer is associated with a prothrombotic state and increases the risk of thrombotic events in patients with atrial fibrillation. We described the clinical characteristics and outcomes and assessed the safety and efficacy of apixaban versus war ... Full text Link to item Cite

Peripheral Artery Disease and Cardiovascular Risk in Patients Presenting With Chest Pain: Insights From the PROMISE Trial

Conference · 2017 Introduction: Peripheral artery disease (PAD) is considered a coronary risk equivalent and is associated with increased risk of adverse cardiovascular (CV) events. Yet, as compared to other high-risk groups, little is known about the relative risk of adver ... Cite

Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial

Conference · 2017 Introduction: Clinically, inconclusive (IC) noninvasive diagnostic tests (NITs) are not infrequent in patients with suspected coronary artery disease, but the actual prevalence and impact of such tests are unclear.Methods: The PROMISE trial randomized 4677 ... Cite

NMR Lipoprotein Profiling Identifies HDL Subclasses Associated With Obstructive CAD: Insights From the PROMISE Clinical Trial

Conference · 2017 Introduction: In patients at high CV risk, the molar sum of concentrations of small and medium HDL subclasses (HMSP) has significant protective associations with CV outcomes, and outperforms HDL cholesterol for risk prediction. The association of HMSP with ... Cite

High Sensitivity Troponin I Measurement in Symptomatic Outpatients With Suspected Coronary Artery Disease: Results From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Study

Conference · 2017 Introduction: Higher concentrations of troponin (Tn) I are associated with prevalent coronary artery disease (CAD) in patients with myocardial infarction. The meaning of TnI concentrations in less acute patients is not well-understood.Hypothesis: Among sym ... Cite

TCT-699 Anatomic Deployment Index: A Novel Measure of SAPIEN 3 Transcatheter Heart Valve Performance

Conference Journal of the American College of Cardiology · November 2016 Full text Cite

Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.

Conference Oncologist · February 2016 BACKGROUND: Anthracycline-containing chemotherapy (Anth-C) is associated with long-term cardiovascular mortality. Although cardiovascular risk assessment has traditionally focused on the heart, evidence has demonstrated that vascular dysfunction also occur ... Full text Link to item Cite

Changes in Medical Therapy and Lifestyle After Anatomical Versus Functional Testing for Coronary Artery Disease: The PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)

Conference · November 10, 2015 Introduction: Diagnostic testing may represent a “teachable moment” for patients newly presenting with symptoms suggestive of CAD and requiring further evaluation, and may influence risk factor management, independent of test results. However, little is kn ... Open Access Link to item Cite

Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States.

Conference Am Heart J · August 2013 BACKGROUND: New percutaneous coronary intervention (PCI) device technologies are often rapidly adopted into clinical practice, yet few studies have examined the overall impact of these new technologies on patient outcomes in community practice. METHODS: In ... Full text Link to item Cite

Sex-based differences in mortality following acute coronary syndromes

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 11, 2008 Link to item Cite

Sex differences in clinical presentation and angiographic data in acute coronary syndromes

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 11, 2008 Link to item Cite

Underuse of left ventricular function assessment in patients with newly diagnosed heart failure

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 11, 2008 Link to item Cite